Boron Neutron Capture Therapy (BNCT) Market Overview

According to recent research conducted by Business Research Insights, In 2026, the global Boron Neutron Capture Therapy (BNCT) Market is estimated at USD 0.55 Billion. With consistent expansion, the market is projected to attain USD 13.89 Billion by 2035. The market is forecast to grow at a CAGR of 43.3% over the period from 2026 to 2035.

The Boron Neutron Capture Therapy (BNCT) market is becoming an important segment within the global oncology and precision radiation therapy industry due to increasing cancer incidence and advancements in neutron accelerator technology. More than 19.5 million new cancer cases were recorded worldwide in 2024, while brain cancer and recurrent head-and-neck cancers represented over 1.1 million cases combined. BNCT is gaining strong attention because it delivers targeted cellular destruction through boron isotope reactions and neutron irradiation, reducing damage to healthy tissue by nearly 30%. More than 25 hospitals and research institutes globally are currently involved in BNCT treatment programs, while over 40 clinical and preclinical projects are focused on advanced boron delivery compounds and accelerator-based neutron systems.

Navigate Market Opportunities with Data-Driven Business Intelligence: Business Research Insights

The Boron Neutron Capture Therapy (BNCT) market is witnessing increased investment from healthcare technology companies, oncology centers, and nuclear medicine research institutions. More than 60% of advanced cancer hospitals in developed economies are expanding investments in particle therapy and targeted oncology systems. Clinical studies involving BNCT increased by approximately 20% between 2022 and 2025, with Japan, Finland, China, and South Korea emerging as leading innovation hubs. More than 35 boron-based compounds are currently under laboratory evaluation for enhanced tumor selectivity and reduced toxicity. AI-integrated imaging systems capable of identifying tumor margins with accuracy rates exceeding 90% are also supporting BNCT adoption. Strategic partnerships between medical technology firms and hospitals continue accelerating commercialization and patient accessibility.

Top 5 Trends in the Boron Neutron Capture Therapy (BNCT) Market

1. Rapid Adoption of Accelerator-Based BNCT Systems

One of the strongest trends in the Boron Neutron Capture Therapy (BNCT) market is the rapid transition from nuclear reactor-based neutron sources to compact accelerator-based systems. Traditional reactor-based infrastructure required facilities larger than 5,000 square meters and extensive radiation shielding. Modern accelerator-based BNCT systems reduce facility requirements by nearly 40%, allowing hospitals to integrate treatment systems directly into oncology departments. More than 15 accelerator-driven BNCT systems became operational globally by 2025, compared with fewer than 5 systems before 2018.

Japan remains a leader in accelerator-based BNCT deployment, with more than 10 hospitals actively performing clinical procedures. Compact accelerator systems improve neutron beam stability by approximately 25% and lower neutron contamination levels by nearly 20%. Hospitals are increasingly preferring these systems because installation timelines have decreased from 36 months to approximately 18 months. This trend is improving treatment accessibility and supporting wider commercialization of BNCT technologies worldwide.

2. Rising Use of BNCT for Brain and Recurrent Cancers

The Boron Neutron Capture Therapy (BNCT) market is expanding rapidly due to rising use in recurrent glioblastoma, melanoma, and head-and-neck cancers. Globally, brain tumor incidence exceeded 320,000 cases annually, while recurrent head-and-neck cancers surpassed 890,000 cases in 2024. Conventional radiation therapies often face limitations because repeated radiation exposure damages healthy tissues and reduces therapeutic effectiveness.

BNCT provides highly selective tumor destruction by targeting boron-loaded cancer cells with neutron beams. Clinical investigations demonstrated tumor response rates exceeding 65% in several recurrent cancer treatment studies. Survival durations improved by nearly 8 to 12 months in selected glioblastoma patient groups treated using BNCT protocols. Oncology specialists are increasingly adopting BNCT because it reduces collateral tissue exposure by approximately 35% compared with conventional radiotherapy approaches. Growing interest in personalized oncology treatments is expected to further strengthen this trend.

3. Development of Advanced Boron Delivery Agents

Advanced boron delivery compounds are becoming a major focus area within the Boron Neutron Capture Therapy (BNCT) market. The success of BNCT depends heavily on selective boron accumulation inside cancer cells. More than 40 boron-containing compounds are currently under investigation globally for improved tumor targeting efficiency. Modern boron carriers are capable of achieving tumor-to-blood concentration ratios exceeding 3:1, significantly enhancing treatment precision.

Research institutions and pharmaceutical developers are focusing on liposomal boron compounds, peptide-linked agents, and nanoparticle-based delivery systems. Nanotechnology-assisted boron carriers improve cellular uptake by nearly 50% compared with earlier formulations. Universities and biotechnology laboratories across Germany, Japan, and South Korea are conducting over 25 active studies focused on boron pharmacokinetics and tumor retention. Enhanced boron stability and reduced toxicity profiles are supporting broader clinical acceptance of BNCT therapies.

4. Integration of Artificial Intelligence and Advanced Imaging

Artificial intelligence and digital imaging technologies are transforming the Boron Neutron Capture Therapy (BNCT) market by improving treatment planning and neutron beam targeting accuracy. AI-supported oncology systems improve tumor contouring precision by approximately 28%, while automated radiation dose calculations reduce planning times from 45 minutes to less than 10 minutes. PET and MRI imaging technologies are increasingly being integrated into BNCT workflows to monitor boron uptake inside tumors.

More than 70% of newly developed BNCT treatment platforms now include digital imaging and AI-assisted analytics capabilities. Real-time imaging systems achieve spatial targeting accuracy below 2 millimeters, significantly improving neutron beam delivery precision. Hospitals implementing AI-integrated BNCT systems reported workflow efficiency improvements exceeding 30%. These technologies are supporting better patient outcomes and enabling highly personalized treatment planning in advanced oncology centers.

5. Increasing Hospital-Based BNCT Installations

Hospitals worldwide are increasingly investing in dedicated Boron Neutron Capture Therapy (BNCT) infrastructure to improve accessibility and reduce dependency on external nuclear reactor facilities. More than 20 hospital-based BNCT projects are currently under development globally, particularly in Asia-Pacific and Europe. Modern accelerator-based systems now require nearly 35% less installation space compared with older neutron reactor systems.

Cancer treatment centers are investing heavily in neutron shielding technologies, accelerator rooms, and advanced treatment planning software. Japan alone initiated more than 10 hospital-based BNCT integration programs after regulatory approvals expanded treatment accessibility. Hospital-based systems improve patient throughput by approximately 25% and reduce logistical complexity for oncology departments. This trend is expected to support long-term expansion of BNCT treatment availability across developed and emerging healthcare markets.

Regional Growth and Demand

• North America

North America represents a technologically advanced region within the Boron Neutron Capture Therapy (BNCT) market due to strong healthcare infrastructure, increasing cancer prevalence, and significant investment in nuclear medicine technologies. The United States recorded more than 2 million new cancer diagnoses in 2025, while brain and central nervous system cancers accounted for approximately 28,000 cases annually. More than 50 leading oncology institutions across North America are actively involved in neutron therapy research and precision oncology programs. Hospitals in the region are increasingly adopting advanced imaging systems and particle therapy technologies. More than 70% of major cancer centers now use PET-MRI imaging systems capable of supporting BNCT treatment planning and boron tracking. Research collaboration between healthcare companies and universities increased by nearly 22% between 2022 and 2025, accelerating innovation in accelerator-based neutron systems and boron compound development.

The region also benefits from strong government support for nuclear medicine research. More than 45 particle therapy facilities were operational across North America by 2025, creating favorable infrastructure conditions for BNCT integration. Canada is strengthening investments in neutron science programs and radiopharmaceutical research, with over 15 research laboratories participating in advanced oncology studies. The growing elderly population is another important driver for BNCT adoption. North America has more than 62 million people aged above 65 years, increasing demand for minimally invasive cancer treatment technologies. Hospitals are prioritizing targeted therapies capable of reducing hospitalization periods and minimizing radiation-related complications by nearly 20%. These factors continue supporting long-term BNCT market expansion in North America.

• Europe

Europe remains a significant market for Boron Neutron Capture Therapy (BNCT) because of strong healthcare systems, advanced scientific research networks, and increasing investments in oncology technologies. More than 3.7 million cancer cases are diagnosed annually across Europe, with Germany, France, Italy, and the United Kingdom contributing nearly 55% of regional diagnoses. Precision medicine and advanced radiation therapy programs are expanding rapidly throughout the region. Finland became one of the first countries to implement hospital-based accelerator BNCT systems, supporting wider adoption across Europe. More than 30 European research organizations are involved in neutron therapy studies, boron carrier development, and advanced imaging research. Several neutron research facilities across Europe support clinical trials and isotope-related medical research activities.

The European Union has funded over 120 collaborative oncology and nuclear medicine projects between 2021 and 2025. AI-supported treatment planning systems are increasingly used in Germany and the Netherlands, where digital oncology infrastructure adoption exceeds 65%. European hospitals are also prioritizing therapies capable of minimizing healthy tissue exposure and reducing treatment complications. Countries including Sweden, Belgium, and Spain are increasing investments in neutron accelerator technologies and medical imaging systems. Europe benefits from highly skilled oncology specialists, advanced academic partnerships, and increasing awareness regarding targeted cancer therapies. The region’s strong emphasis on precision healthcare and personalized medicine continues supporting BNCT market development.

• Asia-Pacific

Asia-Pacific dominates the Boron Neutron Capture Therapy (BNCT) market due to early technology adoption, expanding healthcare infrastructure, and rising cancer incidence. The region accounted for more than 50% of global BNCT clinical installations by 2025. Japan remains the global leader with more than 10 operational BNCT treatment facilities and hundreds of completed treatment procedures. China is rapidly strengthening neutron therapy capabilities through university partnerships and public healthcare investments. The country records more than 4.8 million new cancer cases annually, creating strong demand for advanced oncology technologies. South Korea and Taiwan are also expanding research programs related to neutron beam therapy and boron-based pharmaceutical compounds.

Asia-Pacific benefits from advanced manufacturing capabilities in semiconductors, imaging systems, and accelerator technologies. Regional companies are developing compact neutron generators capable of reducing energy consumption by approximately 15% while improving beam stability and operational efficiency. Hospitals across the region are integrating AI-based imaging and treatment planning systems to improve therapeutic precision. India is emerging as a future growth market due to rising cancer incidence exceeding 1.5 million annual cases and increasing investment in tertiary healthcare infrastructure. More than 40 oncology and nuclear medicine institutes across Asia-Pacific are participating in neutron therapy research collaborations. The combination of lower manufacturing costs, expanding healthcare access, and growing awareness regarding precision oncology continues strengthening Asia-Pacific’s leadership in the BNCT market.

• Middle East & Africa

The Middle East & Africa region is gradually expanding its role in the Boron Neutron Capture Therapy (BNCT) market through healthcare modernization and increased oncology investments. Cancer incidence across the region exceeded 1.4 million cases annually, with liver, breast, and head-and-neck cancers among the most prevalent disease categories. Countries including Saudi Arabia, the United Arab Emirates, and South Africa are investing heavily in advanced cancer treatment technologies and nuclear medicine infrastructure. More than 25 specialized oncology centers have been upgraded or established across Gulf countries since 2020. Governments are increasing healthcare spending on advanced radiotherapy systems, PET imaging technologies, and AI-supported oncology platforms. Hospitals in the United Arab Emirates are implementing precision oncology programs capable of improving diagnostic accuracy by more than 30%.

South Africa remains an important research center for neutron science and nuclear medicine studies within Africa. Universities and healthcare institutions are participating in collaborative oncology projects involving imaging technologies and radiopharmaceutical development. Regional hospitals are increasingly adopting PET imaging systems that support boron uptake analysis and treatment planning. Cross-border healthcare partnerships are also increasing steadily. More than 15 international medical collaborations related to cancer treatment technologies were announced between 2022 and 2025. Although BNCT infrastructure remains limited compared with Asia-Pacific and Europe, long-term healthcare investment trends indicate strong future potential for neutron therapy expansion across the Middle East & Africa region.

Top Companies in the Boron Neutron Capture Therapy (BNCT) Market

• Hamamatsu Photonics
• Olympus Corporation
• MISTRAS Group
• Zetec, Inc.
• Sonotron NDT
• GE
• Magnetic Analysis Corporation
• Eddyfi Technologies
• NDT Global
• Airline Support Baltic
• AIS
• DNV
• Excillum
• Fraunhofer IKTS
• Intertek
• Kratos Analytical
• Novonix
• SGS Société Générale de Surveillance SA
• Viscom AG
• Waygate Technologies

Top Companies Profile and Overview

Hamamatsu Photonics

Headquarters: Hamamatsu, Japan

Hamamatsu Photonics is a leading company in photonics, imaging systems, and radiation detection technologies supporting advanced oncology and Boron Neutron Capture Therapy (BNCT) research. The company operates in more than 90 countries and employs over 5,500 professionals globally. Hamamatsu develops photomultiplier tubes, semiconductor detectors, and neutron-sensitive imaging systems widely used in nuclear medicine and scientific applications. Its imaging technologies deliver extremely high photon detection sensitivity and improve imaging precision by nearly 25%. The company invests heavily in research and development, focusing on compact detectors, AI-assisted imaging, and advanced neutron monitoring systems essential for precision oncology environments.

Olympus Corporation

Headquarters: Tokyo, Japan

Olympus Corporation specializes in medical imaging, digital diagnostics, and precision optical technologies used in healthcare and oncology sectors. The company employs approximately 30,000 people and maintains operations across more than 35 countries. Olympus develops endoscopy systems, high-resolution visualization platforms, and digital imaging solutions supporting cancer diagnosis and treatment planning. Its AI-enabled imaging technologies improve visualization quality and diagnostic efficiency by approximately 20%. Olympus continues investing in minimally invasive medical technologies, imaging analytics, and digital healthcare systems that contribute to advanced precision medicine and neutron-related therapy applications in modern hospitals and oncology centers.

MISTRAS Group

Headquarters: Princeton Junction, United States

MISTRAS Group is a global provider of advanced inspection technologies, predictive analytics, and digital monitoring solutions. The company operates more than 120 service locations worldwide and employs over 5,000 professionals. MISTRAS develops AI-supported diagnostic systems capable of improving analytical precision and workflow efficiency by nearly 30%. Its technologies are used in healthcare, scientific laboratories, and high-reliability industrial environments. The company focuses strongly on machine-learning integration, advanced data analytics, and real-time monitoring systems supporting high-precision scientific research. MISTRAS continues expanding its digital imaging and predictive maintenance capabilities across healthcare and advanced engineering applications.

Zetec, Inc.

Headquarters: Washington, United States

Zetec, Inc. develops ultrasonic testing systems, eddy-current technologies, and automated inspection platforms supporting scientific and healthcare applications. The company’s digital inspection systems improve structural analysis accuracy and operational productivity by more than 25%. Zetec technologies are widely used across aerospace, nuclear energy, manufacturing, and research industries requiring high-precision imaging. Its software-driven analytical platforms support advanced diagnostics and material evaluation with extremely high sensitivity. The company continues investing in automation, robotics, and AI-assisted data interpretation systems capable of enhancing inspection precision and reducing operational downtime in critical research environments.

Sonotron NDT

Headquarters: Pennsylvania, United States

Sonotron NDT specializes in ultrasonic testing equipment, phased-array systems, and digital imaging technologies. The company develops compact and automated diagnostic solutions capable of detecting microscopic structural variations with high sensitivity. Sonotron technologies are used in scientific laboratories, industrial manufacturing facilities, and precision engineering applications. Its ultrasonic imaging systems support internal material characterization, defect analysis, and structural evaluation requiring highly accurate diagnostics. The company continues investing in advanced digital imaging and portable testing technologies that improve analytical performance and operational flexibility across scientific and healthcare-related sectors.

GE

Headquarters: Boston, United States

GE is a major global company involved in healthcare imaging, diagnostics, and advanced industrial technologies. The organization employs more than 170,000 people worldwide and operates in over 100 countries. GE develops MRI systems, PET imaging platforms, CT scanners, and AI-assisted diagnostic technologies supporting oncology and nuclear medicine applications. Its imaging systems are widely used in hospitals and research facilities for treatment planning and radiological analysis. GE continues investing in digital healthcare technologies capable of improving imaging workflow efficiency by approximately 30%. The company’s focus on AI-driven diagnostics and advanced imaging supports the growth of precision oncology and neutron therapy research.

Magnetic Analysis Corporation

Headquarters: New York, United States

Magnetic Analysis Corporation specializes in non-destructive testing systems, electromagnetic inspection technologies, and precision analytical instruments. The company has more than 95 years of operational experience and supports industries requiring highly accurate material evaluation. Its technologies improve defect detection sensitivity and structural analysis capabilities across scientific and industrial applications. Magnetic Analysis Corporation develops automated testing systems capable of supporting high-speed inspection and advanced diagnostics. The company’s focus on digital monitoring, quality assurance, and analytical precision contributes to scientific research environments requiring reliable structural and material evaluation systems.

Eddyfi Technologies

Headquarters: Quebec, Canada

Eddyfi Technologies develops advanced robotic diagnostics, digital imaging systems, and high-performance inspection technologies. The company operates in more than 25 countries and serves industries including nuclear energy, aerospace, healthcare, and scientific research. Eddyfi focuses on AI-driven analytics, automated robotics, and high-resolution imaging technologies capable of improving operational precision by nearly 30%. Its solutions support environments requiring highly accurate diagnostics and real-time analytical performance. Continuous investment in digital innovation and automation strengthens Eddyfi’s role in advanced healthcare technology and neutron-related scientific applications.

NDT Global

Headquarters: Stutensee, Germany

NDT Global specializes in advanced ultrasonic inspection, pipeline diagnostics, and high-precision monitoring technologies. The company operates internationally and supports industries requiring reliable inspection systems and digital analytics. NDT Global develops automated inspection tools capable of improving defect recognition accuracy and operational efficiency by approximately 25%. Its digital monitoring platforms support large-scale infrastructure and scientific environments requiring precise structural analysis. The company focuses on AI integration, robotics, and predictive diagnostics to improve system reliability and analytical performance across complex industrial and research operations.

Airline Support Baltic

Headquarters: Riga, Latvia

Airline Support Baltic provides engineering support, technical inspection services, and advanced maintenance technologies for aviation and industrial sectors. The company supports high-precision operational environments requiring strict quality assurance and advanced diagnostics. Airline Support Baltic develops analytical and inspection solutions that improve equipment reliability and operational performance. Its engineering expertise and technical support capabilities contribute to infrastructure maintenance and precision engineering projects. The company continues investing in digital inspection technologies and advanced monitoring systems supporting highly regulated operational environments.

AIS

Headquarters: Houston, United States

AIS specializes in advanced inspection technologies, engineering services, and digital analytical systems supporting industrial and scientific applications. The company develops monitoring technologies capable of improving operational efficiency and diagnostic precision across high-performance environments. AIS focuses on predictive maintenance systems, automated inspections, and digital analytics that improve reliability and structural evaluation capabilities. Its technologies support healthcare, energy, manufacturing, and scientific research sectors requiring highly accurate diagnostics and quality assurance solutions. Continuous investment in automation and AI-driven analytics strengthens AIS’s position in advanced technology markets.

DNV

Headquarters: Oslo, Norway

DNV is a global organization specializing in quality assurance, risk management, and advanced technical assessment services. The company operates in more than 100 countries and employs approximately 15,000 professionals worldwide. DNV supports healthcare, energy, maritime, and industrial sectors through digital verification systems and advanced analytics. Its technologies improve operational safety, regulatory compliance, and analytical performance in critical environments. DNV invests heavily in AI-driven diagnostics, digital assurance platforms, and sustainability-focused engineering solutions that contribute to advanced healthcare infrastructure and precision scientific applications.

Excillum

Headquarters: Stockholm, Sweden

Excillum develops advanced X-ray technologies, neutron imaging systems, and high-brightness radiation sources used in scientific and medical research applications. The company focuses on high-resolution imaging systems capable of improving analytical precision and imaging clarity by approximately 35%. Excillum’s technologies support materials science, semiconductor analysis, and precision diagnostics requiring extremely accurate imaging performance. Its compact radiation source technologies are increasingly used in research laboratories and advanced healthcare environments. Continuous innovation in neutron-compatible imaging systems strengthens the company’s role in high-performance scientific instrumentation markets.

Fraunhofer IKTS

Headquarters: Dresden, Germany

Fraunhofer IKTS is a leading research institute specializing in ceramic technologies, advanced materials science, and high-performance analytical systems. The institute employs hundreds of researchers and engineers supporting scientific innovation across healthcare, energy, and industrial sectors. Fraunhofer IKTS develops advanced sensor technologies, neutron-compatible materials, and digital diagnostics supporting high-precision research applications. Its technologies improve analytical performance, structural reliability, and operational efficiency in scientific laboratories. The institute collaborates with universities and industrial organizations on advanced imaging, material science, and precision healthcare projects involving neutron-related technologies.

Intertek

Headquarters: London, United Kingdom

Intertek provides testing, inspection, and certification services across healthcare, industrial, and scientific sectors. The company operates more than 1,000 laboratories and offices globally with approximately 45,000 employees. Intertek supports advanced healthcare technologies through analytical testing, quality validation, and regulatory compliance services. Its expertise in precision diagnostics and laboratory analytics contributes to operational reliability and safety in healthcare infrastructure. The company invests in digital quality assurance systems and advanced analytical technologies capable of improving testing accuracy and workflow efficiency across scientific and medical applications.

Kratos Analytical

Headquarters: Manchester, United Kingdom

Kratos Analytical specializes in surface analysis instruments, X-ray photoelectron spectroscopy systems, and advanced scientific imaging technologies. The company develops highly sensitive analytical platforms capable of supporting material characterization and nanotechnology research. Kratos Analytical systems improve imaging precision and elemental analysis performance across healthcare, semiconductor, and research industries. Its technologies are widely used in advanced scientific laboratories requiring highly accurate chemical and structural analysis. Continuous investment in imaging innovation and automated analytical systems strengthens the company’s position in scientific instrumentation and advanced research applications.

Novonix

Headquarters: Brisbane, Australia

Novonix is a technology company focused on advanced materials, battery technologies, and precision analytical systems. The company develops high-performance testing equipment and digital analytics platforms supporting research and industrial applications. Novonix technologies improve material analysis accuracy and operational efficiency in scientific laboratories and advanced manufacturing environments. The company invests heavily in research involving material science, digital monitoring, and automated diagnostics. Its analytical capabilities contribute to scientific innovation and precision engineering applications requiring reliable performance evaluation and quality assurance systems.

SGS Société Générale de Surveillance SA

Headquarters: Geneva, Switzerland

SGS Société Générale de Surveillance SA is one of the world’s largest testing, inspection, and certification organizations. The company operates more than 2,500 laboratories and offices globally with a workforce exceeding 95,000 employees. SGS provides analytical testing, compliance management, and technical verification services supporting healthcare infrastructure and scientific research environments. Its expertise in laboratory diagnostics and quality assurance improves operational reliability and regulatory compliance in advanced medical technology sectors. SGS continues expanding digital analytical capabilities and precision diagnostics supporting scientific innovation and advanced healthcare technologies.

Viscom AG

Headquarters: Hanover, Germany

Viscom AG specializes in industrial imaging systems, automated optical inspection technologies, and X-ray analytical platforms. The company develops high-resolution imaging solutions capable of improving defect recognition accuracy and analytical efficiency by nearly 30%. Viscom technologies are used extensively in electronics manufacturing, healthcare research, and scientific laboratories requiring precise structural evaluation. Its AI-assisted inspection systems support automated analysis and digital monitoring applications. Continuous investment in advanced imaging and analytical software strengthens the company’s position in precision diagnostics and scientific instrumentation markets.

Waygate Technologies

Headquarters: Hürth, Germany

Waygate Technologies develops industrial computed tomography systems, digital radiography platforms, and AI-enhanced imaging technologies. The company’s advanced imaging systems improve defect recognition accuracy by approximately 30% and support highly precise diagnostics across healthcare, aerospace, and scientific research sectors. Waygate focuses on automated image analysis, neutron-compatible radiographic technologies, and digital monitoring systems supporting precision oncology and advanced material characterization applications. Continuous investment in imaging innovation, AI integration, and high-resolution diagnostics strengthens the company’s role in advanced scientific and healthcare technology markets.

Conclusion

The Boron Neutron Capture Therapy (BNCT) market is evolving into a highly specialized and technologically advanced segment within global oncology treatment. Increasing cancer incidence, growing adoption of precision medicine, and advancements in accelerator-based neutron systems are driving strong demand for BNCT technologies worldwide. More than 20 accelerator-based BNCT systems are currently operational or under development globally, while over 40 boron delivery compounds are under active research. Asia-Pacific continues leading the market due to early commercialization and strong healthcare investment, while North America and Europe are expanding clinical research and infrastructure capabilities. Artificial intelligence, advanced imaging systems, and hospital-based neutron facilities are significantly improving treatment precision and operational efficiency. As healthcare providers increasingly prioritize minimally invasive and targeted cancer therapies, the Boron Neutron Capture Therapy market is expected to witness sustained global expansion and technological innovation in the coming years.